BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 17053061)

  • 1. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.
    Chan RJ; Feng GS
    Blood; 2007 Feb; 109(3):862-7. PubMed ID: 17053061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
    Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
    Fragale A; Tartaglia M; Wu J; Gelb BD
    Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
    Chan G; Kalaitzidis D; Neel BG
    Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germ-line and somatic PTPN11 mutations in human disease.
    Tartaglia M; Gelb BD
    Eur J Med Genet; 2005; 48(2):81-96. PubMed ID: 16053901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Noonan syndrome and Leopard syndrome linked to mutation of the gene PTPN11].
    Dereure O
    Ann Dermatol Venereol; 2005 Apr; 132(4):400. PubMed ID: 15886577
    [No Abstract]   [Full Text] [Related]  

  • 7. Noonan syndrome mutation Q79R in Shp2 increases proliferation of valve primordia mesenchymal cells via extracellular signal-regulated kinase 1/2 signaling.
    Krenz M; Yutzey KE; Robbins J
    Circ Res; 2005 Oct; 97(8):813-20. PubMed ID: 16166557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP-2 and myeloid malignancies.
    Tartaglia M; Niemeyer CM; Shannon KM; Loh ML
    Curr Opin Hematol; 2004 Jan; 11(1):44-50. PubMed ID: 14676626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTPN11 mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13.
    Maheshwari M; Belmont J; Fernbach S; Ho T; Molinari L; Yakub I; Yu F; Combes A; Towbin J; Craigen WJ; Gibbs R
    Hum Mutat; 2002 Oct; 20(4):298-304. PubMed ID: 12325025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation.
    Araki T; Mohi MG; Ismat FA; Bronson RT; Williams IR; Kutok JL; Yang W; Pao LI; Gilliland DG; Epstein JA; Neel BG
    Nat Med; 2004 Aug; 10(8):849-57. PubMed ID: 15273746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
    Loh ML; Vattikuti S; Schubbert S; Reynolds MG; Carlson E; Lieuw KH; Cheng JW; Lee CM; Stokoe D; Bonifas JM; Curtiss NP; Gotlib J; Meshinchi S; Le Beau MM; Emanuel PD; Shannon KM
    Blood; 2004 Mar; 103(6):2325-31. PubMed ID: 14644997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction.
    Gelb BD; Tartaglia M
    Hum Mol Genet; 2006 Oct; 15 Spec No 2():R220-6. PubMed ID: 16987887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
    Niihori T; Aoki Y; Ohashi H; Kurosawa K; Kondoh T; Ishikiriyama S; Kawame H; Kamasaki H; Yamanaka T; Takada F; Nishio K; Sakurai M; Tamai H; Nagashima T; Suzuki Y; Kure S; Fujii K; Imaizumi M; Matsubara Y
    J Hum Genet; 2005; 50(4):192-202. PubMed ID: 15834506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia.
    Yamamoto T; Isomura M; Xu Y; Liang J; Yagasaki H; Kamachi Y; Kudo K; Kiyoi H; Naoe T; Kojma S
    Leuk Res; 2006 Sep; 30(9):1085-9. PubMed ID: 16533526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic Drosophila models of Noonan syndrome causing PTPN11 gain-of-function mutations.
    Oishi K; Gaengel K; Krishnamoorthy S; Kamiya K; Kim IK; Ying H; Weber U; Perkins LA; Tartaglia M; Mlodzik M; Pick L; Gelb BD
    Hum Mol Genet; 2006 Feb; 15(4):543-53. PubMed ID: 16399795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3-bp deletion mutation of PTPN11 in an infant with severe Noonan syndrome including hydrops fetalis and juvenile myelomonocytic leukemia.
    Yoshida R; Miyata M; Nagai T; Yamazaki T; Ogata T
    Am J Med Genet A; 2004 Jul; 128A(1):63-6. PubMed ID: 15211660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome.
    Ferreira LV; Souza SA; Arnhold IJ; Mendonca BB; Jorge AA
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5156-60. PubMed ID: 15956085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline gain-of-function mutations in SOS1 cause Noonan syndrome.
    Roberts AE; Araki T; Swanson KD; Montgomery KT; Schiripo TA; Joshi VA; Li L; Yassin Y; Tamburino AM; Neel BG; Kucherlapati RS
    Nat Genet; 2007 Jan; 39(1):70-4. PubMed ID: 17143285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noonan syndrome and related disorders: genetics and pathogenesis.
    Tartaglia M; Gelb BD
    Annu Rev Genomics Hum Genet; 2005; 6():45-68. PubMed ID: 16124853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.
    Tartaglia M; Mehler EL; Goldberg R; Zampino G; Brunner HG; Kremer H; van der Burgt I; Crosby AH; Ion A; Jeffery S; Kalidas K; Patton MA; Kucherlapati RS; Gelb BD
    Nat Genet; 2001 Dec; 29(4):465-8. PubMed ID: 11704759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.